Veeva Systems Sees AI as Growth Engine Beyond Its $6B 2030 Revenue Target

Key Points

• AI is positioned as incremental growth beyond Veeva’s $6 billion 2030 revenue target. The company is developing Vault AI for embedded assistance and Falcon for agentic workflow automation, with monetization expected to vary from token-based consumption to outcome-based pricing and enterprise licenses.
• Veeva is seeing expanding adoption across its product portfolio, including more than 180 customers live on Vault CRM and an above-80% CRM win rate outside the top 20 pharmaceutical companies. The company expects to retain more than 70% of the life-sciences CRM market over time.
• Additional growth opportunities include newer clinical products, CRO-led trial-by-trial sales and horizontal-market expansion through Aspen CRM. Veeva expects its first Falcon customer to go live later this year and its first top-20 pharmaceutical deployment in the first half of next year.

Veeva Systems NYSE: VEEV is positioning artificial intelligence as an incremental growth opportunity beyond its previously stated goal of reaching $6 billion in revenue by 2030, according to executives speaking at a Wells Fargo healthcare technology event.

Paul Shawah, Veeva’s EVP of Commercial Strategy, said the company is continuing to build an industry cloud for life sciences that combines applications, data, agents and consulting across research and development and commercial operations. Its R&D offerings span clinical, quality, regulatory and safety functions, while its commercial portfolio includes CRM, content and data products.

Shawah said Veeva’s more recent focus on AI represents a “major shift” for the company. Veeva’s AI strategy includes Veeva Vault AI, which embeds AI capabilities into its existing applications, and Veeva Falcon, an agentic AI layer intended to perform work within customer workflows.

AI Seen as Incremental to 2030 Target

Veeva’s $6 billion revenue target, issued about two years ago, was primarily based on its existing life-sciences enterprise applications, Shawah said. AI agents and Veeva’s expansion into horizontal markets were not major components of that outlook and are considered incremental opportunities.

Shawah said monetization will likely vary by AI offering and use case. Vault AI, which is designed to help users summarize information, make decisions and work more efficiently, will in most cases be monetized through consumption, such as token usage. Falcon, meanwhile, could be priced based on outcomes, including the number of documents processed or other business transactions. Veeva may also use enterprise license agreements for certain Falcon deployments, he said.

“Our main focus” is maturing the products and establishing their value proposition, Shawah said, adding that the appropriate licensing model should follow from customer adoption. Gunnar Hansen, Veeva’s Head of Investor Relations, said the company is initially focused on getting AI products into customers’ hands and delivering value before determining longer-term revenue models.

Executives cited regulatory communications as one potential Falcon use case. Shawah said drug regulators, including the U.S. Food and Drug Administration, may pause an approval process while seeking answers from a drugmaker. AI agents could help companies develop, translate and consistently deliver responses more quickly across geographies. Faster responses could shorten the time to approval, potentially allowing a product to reach patients and the market sooner.

Veeva has customers using its AI capabilities in core applications and commercial content workflows, Shawah said. The company also has an early lead in Falcon MLR, an agentic product used for review and approval of commercial content that originated through Veeva’s acquisition of Compli. He said Veeva recently had its first top-20 pharmaceutical company begin with a small deployment and expand its agentic call report to its U.S. field force.

Clinical Products and CRO Channel Opportunity

In R&D, Shawah said Veeva’s portfolio includes both more mature offerings and newer products that are in earlier adoption stages. Established products will continue to contribute to growth because they have not reached full market adoption, he said. Newer products, including EDC, Safety, RTSM and eCOA, are earlier in their ramps.

The company also sees an opportunity in trial-by-trial sales through contract research organizations, or CROs. While much of Veeva’s existing revenue comes from enterprise license agreements with larger customers, some clinical-trial customers purchase technology on an individual-trial basis.

Shawah said CROs can serve as both Veeva customers and important channels, particularly among small and midsize life-sciences companies where CROs have substantial influence over technology decisions. However, he said adoption takes time because CROs may have large workforces familiar with legacy systems.

• Some trial sponsors choose the core technology themselves.
• In other cases, especially among smaller companies, CROs recommend technology providers.
• Veeva expects more CROs over time to standardize on its products when making proposals to customers.

Shawah said Veeva is beginning to see benefits from its partnership with IQVIA, one of the largest CROs. The relationship allows Veeva to build connectors between its software and IQVIA data, opening opportunities to resume selling certain products in segments where customers had standardized on IQVIA data.

CRM Momentum and Commercial Portfolio

Shawah said Veeva’s CRM business recorded its best quarter ever, supported by Vault CRM decisions from companies including Lilly, Biogen and Regeneron. Veeva now has more than 180 customers live on Vault CRM, he said, and the company has improved the efficiency of its migration process.

Outside the top 20 pharmaceutical companies, Shawah said Veeva’s CRM win rate has remained above 80% this year for both existing Veeva CRM customers choosing to migrate and companies selecting CRM products for the first time. Veeva expects to retain more than 70% market share in life-sciences CRM over time, he said.

The company also recently introduced Aspen CRM as part of its expansion into horizontal markets. Shawah said Veeva aims to offer a CRM platform that is faster to deploy, less expensive and more transparent in its licensing than competing products.

Within Veeva’s broader Commercial Cloud portfolio, Shawah highlighted Crossix as a strong performer, particularly in measurement and audience products for digital engagement. He also cited continued growth opportunities in commercial content, Link data products and earlier-stage Compass patient and prescriber data offerings.

On AI profitability, Hansen said it remains early to determine Falcon’s margin profile. However, he noted that Falcon margins could become more comparable to Veeva’s subscription margins if the company can use deterministic software for portions of workflows and if token costs decline over time. Veeva expects its first Falcon customer to go live later this year and its first top-20 customer deployment in the first half of next year, Hansen said.

About Veeva Systems (NYSE:VEEV)

Veeva Systems Inc is a cloud software company that provides technology solutions for the life sciences industry, including pharmaceutical, biotechnology, medical device and related organizations. Its applications are designed to support functions across the product lifecycle, from research and clinical development through regulatory approval, manufacturing, quality management and commercial operations.

The company's Veeva Vault platform includes applications for clinical data management, electronic trial management, regulatory information, quality processes, safety operations and commercial content management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.